Article

New weldable pump tube

PureWeld XL from Watson-Marlow, a new weldable and ADCF (animal-derived contents free) tube for use in bio-pharmaceutical processes, provides users with secure joins that allow for a connector-free fluid path. PureWeld demonstrates very low internal spallation and gives long tube life in peristaltic pump applications.

New PureWeld XL is a thermoplastic elastomer tubing designed to deliver purity and performance in single-use bioprocessing applications. PureWeld XL can be securely welded, allowing complete, connector-free fluid paths to be assembled in minutes.

  • Sterile,weldable and heat sealable
  • Animal derived content free
  • Provides very stable flow rates with the lowest spallation
  • FDA CFR 177.1810, USP Class VI and European Pharmacopoeia certification

A high-quality peristaltic pump tubing, PureWeld XL gives users improved pumping performance over many alternative weldable tube products. PureWeld XL is manufactured in a Class J10,000 cleanroom by Watson-Marlow, the world’s leading peristaltic pump manufacturer. Validation and extractables profiles are available.

www.wmtubing.com

info@watson-marlow.co.uk

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
Kratom or Mitragyna speciosa on natural background. | Image Credit: © wasanajai - stock.adobe.com
July 31st 2025

FDA Seeks Scheduling Action to Control Harmful Kratom Plant Byproduct

Patrick Lavery
7-OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
July 31st 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services. | Image Credit: © Tada Images - stock.adobe.com
July 31st 2025

3 Reasons FDA Says Quality Investments Are Essential for Drug Manufacturers and Patients

Patrick Lavery
FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and help prevent drug shortages.
Site Logo
July 31st 2025

Transformations in Drug Development for Cell and Gene Therapies

PPD Thermo Fisher Scientific
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Glass vials for liquid samples. | Image Credit: ©nordroden - stock.adobe.com
July 31st 2025

Flexibility Provides Solutions to Small-Batch Manufacturing Challenges

Susan Haigney
Modular process design, single-use technologies, and flexible filling lines are some of the ways manufacturers can combat challenges involved in small-batch manufacturing.
woman face and hand with syringe making injection | Image Credit: © Syda Productions - stock.adobe.com
July 31st 2025

Boehringer Ingelheim, Re-Vana Therapeutics to Collaborate on Long-Acting Ophthalmic Therapies

Patrick Lavery
Re-Vana’s drug delivery technology is designed to release treatments over a 6- to 12-month period, with the goal of reducing frequency of injections for patients.